Lista de obras -

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.

artículo científico publicado en 2016

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

artículo científico publicado en 2016

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265).

artículo científico publicado en 2015

A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab

artículo científico publicado en 2020

A new paradigm for tumor immune escape: β-catenin-driven immune exclusion

artículo científico publicado en 2015

A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma

artículo científico publicado en 2016

A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma.

artículo científico publicado en 2009

A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma

artículo científico publicado en 2013

ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients

scientific article published on 24 January 2020

Abstract IA10: Effective immunotherapy regimens incorporating highly active human STING-activating cyclic dinucleotide derivatives

Agonist anti-4-1BB plus neutralizing anti-CTLA-4 or -PD-L1 synergize to promote tumor regression by rescuing dying dysfunctional CD8+ T cells within the tumor microenvironment

artículo científico publicado en 2015

Agonistic 4-1bb antibodies in combination with inhibitory antibodies against CTLA-4, PD-L1 or LAG-3 ACT on CD8+ T cells in the tumor microenvironment and synergize to promote regression of established tumors

An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells

artículo científico publicado en 2007

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.

artículo científico publicado en 2018

Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA.

artículo científico publicado en 2016

Back from the dead: TIL apoptosis in cancer immune evasion

artículo científico publicado en 2018

Beta-catenin does not regulate memory T cell phenotype

artículo científico publicado en 2010

Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma.

artículo científico publicado en 2014

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro

article

CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells

artículo científico publicado en 2009

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

artículo científico publicado en 2005

CD40 ligation reverses T cell tolerance in acute myeloid leukemia

artículo científico publicado en 2013

COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19

scientific article published on 26 July 2020

Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.

artículo científico publicado en 2017

Cancer and the Microbiome: Influence of the commensal microbiota on cancer, immune responses, and immunotherapy

artículo científico publicado en 2020

Cancer classification using the Immunoscore: a worldwide task force

artículo científico publicado en 2012

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

artículo científico publicado en 2016

Cellular and Molecular Requirements for Rejection of B16 Melanoma in the Setting of Regulatory T Cell Depletion and Homeostatic Proliferation ⬇️

artículo científico publicado el 6 de febrero de 2012

Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment

artículo científico publicado en 2009

Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer

artículo científico publicado el 1 de diciembre de 2010

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study

artículo científico publicado en 2014

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

artículo científico publicado en 2015

Conditional Deletion of PTEN in Peripheral T Cells Augments TCR-Mediated Activation but Does Not Abrogate CD28 Dependency or Prevent Anergy Induction ⬇️

artículo científico publicado el 12 de julio de 2013

Costimulatory and coinhibitory receptors in anti-tumor immunity

artículo científico publicado en 2009

Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy

artículo científico publicado en 2006

Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells

article

Defining the critical hurdles in cancer immunotherapy

artículo científico publicado en 2011

Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes

artículo científico publicado en 2003

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

artículo científico publicado en 2015

Direct activation of STING in the tumor microenvironment with synthetic cyclic dinucleotide derivatives leads to potent and systemic tumor-specific immunity

Distinct Graft-Specific TCR Avidity Profiles during Acute Rejection and Tolerance

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial

artículo científico publicado en 2014

Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics

artículo científico publicado en 2015

Egr2 targets identify a population of dysfunctional T cells in the tumor microenvironment with immune modulatory properties

artículo científico publicado en 2013

Egr2 targets identify a population of dysfunctional T cells in the tumor microenvironment with immune modulatory properties.

artículo científico publicado en 2014

Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy ⬇️

artículo científico publicado el 30 de marzo de 2013

Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy

artículo científico publicado en 2015

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

artículo científico publicado en 2019

Evidence implicating the commensal microbiota in shaping anti-tumor immunity in melanoma

article

Exploring the emerging role of the microbiome in cancer immunotherapy

scholarly article by Jessica Fessler et al published 17 April 2019 in Journal for Immunotherapy of Cancer

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

artículo científico publicado en 2019

Extremely potent immunotherapeutic activity of a STING agonist in the B16 melanoma model in vivo

artículo científico publicado en 2013

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies

artículo científico publicado en 2017

Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity

artículo científico publicado en 2002

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

artículo científico publicado en 2016

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

artículo científico publicado en 2013

Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".

artículo científico publicado en 2012

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

artículo científico publicado en 2014

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

artículo científico publicado en 2015

High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions

artículo científico publicado en 2018

Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting

artículo científico publicado en 2013

Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection

scientific article published on 01 October 2006

Homeostatic proliferation of naïve CD8+ T cells depends on CD62L/L-selectin-mediated homing to peripheral LN.

artículo científico publicado en 2009

Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma

artículo científico publicado en 2008

Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk

artículo científico publicado en 2016

ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo.

artículo científico publicado en 2005

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin

artículo científico publicado en 2013

Immune resistance orchestrated by the tumor microenvironment

artículo científico publicado en 2006

Immune suppression in the tumor microenvironment

artículo científico publicado en 2006

Immune surveillance is thwarted by tumor-cell intrinsic beta-catenin signaling.

artículo científico publicado en 2015

Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma

artículo científico publicado en 2003

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

artículo científico publicado en 2018

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.

artículo científico publicado en 2016

Immunotherapy with a sting

artículo científico publicado en 2020

Induction of cytotoxic granules in human memory CD8+ T cell subsets requires cell cycle progression

artículo científico publicado en 2006

Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy

article

Innate immune sensing of a growing tumor in vivo occurs via the host sting pathway and involves mitochondrial DNA transfer from cancer cells to DCs.

artículo científico publicado en 2013

Innate immune signaling and regulation in cancer immunotherapy

artículo científico publicado en 2016

Innovations and challenges in melanoma: summary statement from the first Cambridge conference

artículo científico publicado en 2006

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

artículo científico publicado en 2020

Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy

artículo científico publicado en 2004

Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity

artículo científico publicado en 2017

LAG-3 and 4-1BB identify dysfunctional antigen-specific T cells in the tumor microenvironment and combinatorial LAG-3/4-1BB targeting gives synergistic tumor control.

artículo científico publicado en 2015

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

artículo científico publicado en 2015

Lymphatic vessels regulate immune microenvironments in human and murine melanoma

artículo científico publicado en 2016

MYC - a thorn in the side of cancer immunity

artículo científico publicado en 2016

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment

artículo científico publicado en 2014

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

artículo científico publicado en 2016

Melanoma-intrinsic β-catenin signaling prevents T cell infiltration and anti-tumor immunity

artículo científico publicado en 2014

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

artículo científico publicado en 2015

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma

artículo científico publicado en 2014

Molecular regulation of T-cell anergy

artículo científico publicado en 2008

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

artículo científico publicado en 2018

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

artículo científico publicado en 2017

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model

artículo científico publicado en 2009

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)

artículo científico publicado en 2018

Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)

artículo científico publicado en 2020

Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)

artículo científico publicado en 2019

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma

artículo científico publicado en 2019

Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.

artículo científico publicado en 2014

Phase I/II trial of tremelimumab in patients with metastatic melanoma

article

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

artículo científico publicado en 2015

Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma

artículo científico publicado en 2004

Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma ⬇️

artículo científico publicado el 15 de noviembre de 2012

Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers

artículo científico publicado en 2015

Protein kinase Ctheta focusing at the cSMAC is a consequence rather than cause of TCR signaling and is dependent on the MEK/ERK pathway.

artículo científico publicado en 2009

Rational combinations of immunotherapeutics that target discrete pathways

artículo científico publicado en 2013

Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma

artículo científico publicado en 2016

Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM).

artículo científico publicado en 2017

Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics.

artículo científico publicado en 2007

Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer ⬇️

artículo científico publicado en 2011

SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery

artículo científico publicado en 2011

STING pathway agonism as a cancer therapeutic

artículo científico publicado en 2019

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma

artículo científico

Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma

scientific article published on 08 November 2019

Sensitive detection and quantification of SARS-CoV-2 in saliva

artículo científico publicado en 2020

Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial

artículo científico publicado en 2016

T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha

artículo científico publicado en 2006

T cell development and function in CrkL‐deficient mice ⬇️

artículo científico publicado el 1 de octubre de 2003

Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases

artículo científico publicado en 2007

The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment.

artículo científico publicado en 2017

The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer

artículo científico publicado en 2009

The STING pathway and the T cell-inflamed tumor microenvironment

artículo científico publicado en 2015

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma ⬇️

artículo científico publicado el 27 de agosto de 2013

The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.

artículo científico publicado en 2018

The composition of the microbiota modulates allograft rejection

artículo científico publicado en 2016

The host STING pathway at the interface of cancer and immunity

scientific article published on July 2016

The immune score as a new possible approach for the classification of cancer

artículo científico publicado en 2012

The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies

artículo científico publicado en 2018

Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment

artículo científico publicado en 2013

Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo ⬇️

artículo científico publicado el 5 de noviembre de 2012

Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy

artículo científico publicado en 2016

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

artículo científico publicado en 2017

Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells

artículo científico publicado en 2020

Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites

Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy

artículo científico publicado en 2017

Tumor-intrinsic oncogene pathways mediating immune avoidance

artículo científico publicado en 2016

Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy

artículo científico publicado en 2016

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAFV600- mutated melanoma (BRIM7).

artículo científico publicado en 2014

Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells

artículo científico publicado en 2007

WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia

artículo científico publicado en 2018

Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011 ⬇️

artículo científico publicado el 28 de mayo de 2012

β-Catenin Inhibits T Cell Activation by Selective Interference with Linker for Activation of T Cells–Phospholipase C-γ1 Phosphorylation ⬇️

artículo científico publicado el 13 de diciembre de 2010

Lista de obras de

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265).

A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab

A new paradigm for tumor immune escape: β-catenin-driven immune exclusion

A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma

A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma.

A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma

ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients

Abstract IA10: Effective immunotherapy regimens incorporating highly active human STING-activating cyclic dinucleotide derivatives

Agonist anti-4-1BB plus neutralizing anti-CTLA-4 or -PD-L1 synergize to promote tumor regression by rescuing dying dysfunctional CD8+ T cells within the tumor microenvironment

Agonistic 4-1bb antibodies in combination with inhibitory antibodies against CTLA-4, PD-L1 or LAG-3 ACT on CD8+ T cells in the tumor microenvironment and synergize to promote regression of established tumors

An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.

Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA.

Back from the dead: TIL apoptosis in cancer immune evasion

Beta-catenin does not regulate memory T cell phenotype

Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma.

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro

CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

CD40 ligation reverses T cell tolerance in acute myeloid leukemia

COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19

Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.

Cancer and the Microbiome: Influence of the commensal microbiota on cancer, immune responses, and immunotherapy

Cancer classification using the Immunoscore: a worldwide task force

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Cellular and Molecular Requirements for Rejection of B16 Melanoma in the Setting of Regulatory T Cell Depletion and Homeostatic Proliferation ⬇️

Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment

Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

Conditional Deletion of PTEN in Peripheral T Cells Augments TCR-Mediated Activation but Does Not Abrogate CD28 Dependency or Prevent Anergy Induction ⬇️

Costimulatory and coinhibitory receptors in anti-tumor immunity

Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy

Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells

Defining the critical hurdles in cancer immunotherapy

Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

Direct activation of STING in the tumor microenvironment with synthetic cyclic dinucleotide derivatives leads to potent and systemic tumor-specific immunity

Distinct Graft-Specific TCR Avidity Profiles during Acute Rejection and Tolerance

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial

Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics

Egr2 targets identify a population of dysfunctional T cells in the tumor microenvironment with immune modulatory properties

Egr2 targets identify a population of dysfunctional T cells in the tumor microenvironment with immune modulatory properties.

Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy ⬇️

Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

Evidence implicating the commensal microbiota in shaping anti-tumor immunity in melanoma

Exploring the emerging role of the microbiome in cancer immunotherapy

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

Extremely potent immunotherapeutic activity of a STING agonist in the B16 melanoma model in vivo

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies

Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions

Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting

Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection

Homeostatic proliferation of naïve CD8+ T cells depends on CD62L/L-selectin-mediated homing to peripheral LN.

Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma

Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk

ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo.

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin

Immune resistance orchestrated by the tumor microenvironment

Immune suppression in the tumor microenvironment

Immune surveillance is thwarted by tumor-cell intrinsic beta-catenin signaling.

Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.

Immunotherapy with a sting

Induction of cytotoxic granules in human memory CD8+ T cell subsets requires cell cycle progression

Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy

Innate immune sensing of a growing tumor in vivo occurs via the host sting pathway and involves mitochondrial DNA transfer from cancer cells to DCs.